Dark skin - constitutional or pathological? A X-linked Adrenoleukodystrophy case report
DOI:
https://doi.org/10.25753/BirthGrowthMJ.v27.i3.12753Keywords:
Adrenal insufficiency, cerebral demyelination, dark skin, X-linked adrenoleukodystrophyAbstract
Introduction: X-linked adrenoleukodystrophy is a genetically determined peroxisomal disease.
Clinical case: An eleven-year-old boy was referred to a pediatric clinic due to generalized hyperpigmentation beginning at the age of six. By ten years of age he started to present behavior changes and decreased school perfomance. History of cutaneous hyperpigmentation was documented in the boy’s maternal uncle. Blood tests were compatible with adrenal insufficiency. Brain Magnetic Resonance Imaging showed frontal leukoencephalopathy. The elevated plasmatic concentration of very long-chain fatty acids and the genotype sequencing of ABCD1 gene established the diagnosis of X-linked adrenoleukodystrophy. The boy´s general condition improved with adrenal insufficiency corticoesteroid treatment however progressive cognitive function deterioration was maintained.
Discussion/Conclusion: Early diagnosis and treatment of this rare condition is very important as it can change the disease course. In this case report, given the severity of neurological involvement at diagnosis, no treatment was available to halt neurological disease progression.
Downloads
References
Singh I, Pujol A. Pathomechanisms Underlying X-Adrenoleukodystrophy: A Three-Hit Hypothesis. Brain Pathol 2010; 20(4):838-44.
Engelen M, Kemp S, Visser M et al. Clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet Journal of Rare Diseases 2012; 7:51-64
Bezman L, Moser AB, Raymond GV et al. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol 2001; 49(4):512-17
Moser HW. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 1997; 120:1485-508
Cappa M, Bizarri C, Vollono C, Petroni A, Banni S. Adrenoleukodystrophy. Endocr Dev 2011; 20:149-60.
Ronghe MD, Barton J, Jardine PE et al. The importance of testing for adrenoleucodystrophy in males with idiopathic Addison’s disease. Arch Dis Child 2002; 86:185-89
Dubey P, Raymond GV, Moser AB, Kharkar S, Bezman L, Moser HW. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. J Pediatr 2005; 146(4):528-32
Laureti S, Casucci G, Santeusanio F, Angeletti G, Aubourg P, Brunetti P. X-linked adrenoleukodystrophy is a frequent cause of idiopathic Addison's disease in young adult male patients. J Clin Endocrinol Metab 1996; 81(2):470-4
Van der Knaap MS, Valk J: X-linked adrenoleukodystrophy. In: Magnetic Resonance of Myelination and Myelin Disorders. Heilmann U (3rd edition). Berlin-Heidelberg-New York: Springer; 2005:176-90
Berger J, Pujol A, Aubourg P, Forss-Petter S. Current and Future Pharmacological Treatment Strategies in X Linked Adrenoleukodystrophy. Brain Pathol. 2010; 20(4):845-56
Moser HW, Moser AB, Smith KD et al. Adrenoleukodystrophy: phenotypic variability and implications for therapy. J Inherit Metab Dis 1992; 15:645-64
Mahmood A, Dubey P, Moser HW, Moser A. X-linked adrenoleukodystrophy: therapeutic approaches to distinct phenotypes. Pediatr Transplant 2005; 9 Suppl 7:55-62
Engelen M, Ofman R, Dijkgraaf MG, et al. Lovastatin in X-linked adrenoleukodystrophy. N Engl J Med 2010; 362:276-77
Moser HW, Moser AB, Hollandsworth K, Brereton NH, Raymond GV. "Lorenzo's oil" therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy. J Mol Neurosci 2007; 33(1):105-13
Moser HW, Raymond GV, Dubey P. Adrenoleukodystrophy: new approaches to a neurodegenerative disease. JAMA 2005; 294(24):3131-4
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 NASCER E CRESCER - BIRTH AND GROWTH MEDICAL JOURNAL
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in the Birth and Growth Medical Journal are Open Access and meet the requirements of funding agencies and academic institutions. Third-party use of published content is permitted under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) license. It is the responsibility of authors to obtain permission for reproducing figures, tables, or other materials from previously published works.
Authors must submit a Conflict of Interest statement and an Authorship Form together with their manuscript. A confirmation email will be sent to the corresponding author upon receipt of the submission. Authors are also permitted to deposit their articles in institutional or personal repositories, provided that the original publication in the Birth and Growth Medical Journal is clearly indicated and the terms of the Creative Commons license are respected.
